HK1226095B - Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use - Google Patents

Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use Download PDF

Info

Publication number
HK1226095B
HK1226095B HK16114292.8A HK16114292A HK1226095B HK 1226095 B HK1226095 B HK 1226095B HK 16114292 A HK16114292 A HK 16114292A HK 1226095 B HK1226095 B HK 1226095B
Authority
HK
Hong Kong
Prior art keywords
antibodies
protein
cells
antibody
domain
Prior art date
Application number
HK16114292.8A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1226095A1 (en
Inventor
Jaromir Pastorek
Silvia Pastorekova
Miriam Zatovicova
Jan Zavada
Marta Ortova Gut
Zuzanna Zavadova
Original Assignee
Institute Of Virology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Virology filed Critical Institute Of Virology
Publication of HK1226095A1 publication Critical patent/HK1226095A1/en
Publication of HK1226095B publication Critical patent/HK1226095B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16114292.8A 2002-02-21 2016-12-15 Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use HK1226095B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35882402P 2002-02-21 2002-02-21
US358824P 2002-02-21
US38306802P 2002-05-23 2002-05-23
US383068P 2002-05-23
US43149902P 2002-12-05 2002-12-05
US431499P 2002-12-05

Publications (2)

Publication Number Publication Date
HK1226095A1 HK1226095A1 (en) 2017-09-22
HK1226095B true HK1226095B (en) 2017-09-22

Family

ID=33425052

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16114292.8A HK1226095B (en) 2002-02-21 2016-12-15 Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use

Country Status (9)

Country Link
US (5) US7846673B2 (enExample)
EP (1) EP1487972B1 (enExample)
JP (4) JP4488351B2 (enExample)
AU (1) AU2003217606C1 (enExample)
CA (1) CA2477163C (enExample)
DK (2) DK1487972T3 (enExample)
HK (1) HK1226095B (enExample)
HU (3) HUE026218T2 (enExample)
WO (1) WO2004005348A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2508596T1 (sl) * 2002-02-21 2016-01-29 Institute Of Virology Slovak Academy Of Sciences Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe
CA2477163C (en) * 2002-02-21 2010-07-27 Institute Of Virology Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
WO2003089659A1 (en) * 2002-04-16 2003-10-30 The Regents Of The University Of California Methods or renal cell carcinoma prognosis and treatment selection with carbonic anhydrase ix
US20090239247A1 (en) * 2002-12-13 2009-09-24 Harris Adrian L MN and Hypoxia
US8003625B2 (en) 2005-06-29 2011-08-23 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
EP2074225B1 (en) * 2006-10-10 2014-12-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
US8492520B2 (en) * 2007-11-02 2013-07-23 Wilex Ag Binding epitopes for G250 antibody
CN101868445B (zh) 2007-11-19 2014-06-18 旭化成化学株式会社 异氰酸酯和芳香族羟基化合物的制造方法
CA2754072C (en) 2009-03-02 2019-01-15 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
EP2674756B1 (en) * 2009-09-10 2016-08-03 Bruker Daltonik GmbH Determining the expression status of human epidermal growth factor receptor 2 (HER2) in biological samples
CA3214092A1 (en) 2011-03-15 2012-09-20 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
US9080849B2 (en) 2011-07-29 2015-07-14 Milwaukee Electric Tool Corporation Tape measure
CA2784047C (en) 2011-07-29 2015-08-11 Milwaukee Electric Tool Corporation Tape measure
US8863399B2 (en) 2011-08-26 2014-10-21 Milwaukee Electric Tool Corporation Tape measure
EP2508890A1 (en) * 2011-10-25 2012-10-10 Roche Diagnostics GmbH CAIX based diagnosis of heart failure
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
US9267778B2 (en) 2012-01-19 2016-02-23 Milwaukee Electric Tool Corporation Tape measure
US20150005264A1 (en) * 2012-01-31 2015-01-01 Threshold Pharmaceuticals, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
JP2015155795A (ja) * 2012-05-21 2015-08-27 東レ株式会社 癌の検出方法
USD733597S1 (en) 2012-07-30 2015-07-07 Milwaukee Electric Tool Corporation Tape measure
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
JP6847660B2 (ja) * 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
WO2016172612A1 (en) * 2015-04-23 2016-10-27 Cedars-Sinai Medical Center Automated delineation of nuclei for three dimensional (3-d) high content screening
USD785475S1 (en) 2015-12-10 2017-05-02 Milwaukee Electric Tool Corporation Tape measure
USD785476S1 (en) 2015-12-10 2017-05-02 Milwaukee Electric Tool Corporation Tape measure
USD783429S1 (en) 2016-01-07 2017-04-11 Milwaukee Electric Tool Corporation Tape measure
USD787347S1 (en) 2016-01-07 2017-05-23 Milwaukee Electric Tool Corporation Tape measure
USD783430S1 (en) 2016-01-07 2017-04-11 Milwaukee Electric Tool Corporation Tape measure
US11448643B2 (en) 2016-04-08 2022-09-20 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
WO2017193070A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
USD788611S1 (en) 2016-06-01 2017-06-06 Milwaukee Electric Tool Corporation Tape measure
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US11028425B2 (en) 2018-06-08 2021-06-08 Glympse Bio, Inc. Diagnosis and monitoring of liver disease
US11732009B2 (en) 2018-06-08 2023-08-22 Glympse Bio, Inc. Activity sensor with tunable analyte
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
WO2020068920A2 (en) 2018-09-25 2020-04-02 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
WO2020191416A2 (en) 2019-02-28 2020-09-24 Georgia Tech Research Corporation Compositions and methods for logic-gated profiling of biologic activity
EP3966253A4 (en) * 2019-05-06 2023-02-22 Navi Bio-Therapeutics, Inc. ANTI-CARBONIC ANHYDRASE IX ANTIBODIES
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4055056A1 (en) * 2019-11-05 2022-09-14 Mabpro A.S. Humanized anti-ca ix antibodies and methods of their use
CN111273036B (zh) * 2020-03-06 2021-06-15 中国农业科学院兰州兽医研究所 检测口蹄疫非结构蛋白抗体的单抗竞争化学发光试剂盒
CA3194956A1 (en) 2020-09-11 2022-03-17 Glympse Bio, Inc. Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CA3236930A1 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN116167592B (zh) * 2023-04-20 2023-06-23 交通运输部天津水运工程科学研究所 一种河流溢油风险防控和决策支持系统

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5972353A (en) 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US6774117B1 (en) 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6069242A (en) 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6093548A (en) 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5955075A (en) 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
CA2192678C (en) * 1994-06-15 2010-12-14 Jan Zavada Mn gene and protein
US6451977B1 (en) * 1998-02-26 2002-09-17 Genentech, Inc. Fused polypeptides
EP1123387B1 (en) 1998-10-23 2007-10-17 Institute Of Virology Mn gene and protein
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
CA2477163C (en) * 2002-02-21 2010-07-27 Institute Of Virology Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes
AU2003268180A1 (en) 2002-08-23 2004-03-11 Chiron Corporation Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
WO2008103327A2 (en) 2007-02-20 2008-08-28 Bayer Pharmaceuticals Corporation Mn/ca ix and bladder cancer
US8492520B2 (en) * 2007-11-02 2013-07-23 Wilex Ag Binding epitopes for G250 antibody

Also Published As

Publication number Publication date
JP5199228B2 (ja) 2013-05-15
CA2477163C (en) 2010-07-27
US7833728B2 (en) 2010-11-16
JP2013060452A (ja) 2013-04-04
AU2003217606C1 (en) 2008-07-17
JP2005535601A (ja) 2005-11-24
AU2003217606B2 (en) 2007-11-22
HUE036891T2 (hu) 2018-08-28
EP1487972A2 (en) 2004-12-22
US20080177046A1 (en) 2008-07-24
EP1487972B1 (en) 2015-08-12
WO2004005348A1 (en) 2004-01-15
JP4488351B2 (ja) 2010-06-23
US20080176258A1 (en) 2008-07-24
EP1487972A4 (en) 2006-05-31
AU2003217606A2 (en) 2003-12-12
US7816493B2 (en) 2010-10-19
HK1177474A1 (en) 2013-08-23
JP4514820B2 (ja) 2010-07-28
AU2003217606A1 (en) 2003-12-12
CA2477163A1 (en) 2003-12-04
HUE026218T2 (en) 2016-05-30
JP5271443B2 (ja) 2013-08-21
DK3031910T3 (en) 2017-10-23
US20080176310A1 (en) 2008-07-24
JP2010111679A (ja) 2010-05-20
JP2009114198A (ja) 2009-05-28
AU2003217606B8 (en) 2003-12-12
HUE026277T2 (en) 2016-05-30
US7846673B2 (en) 2010-12-07
US20050031623A1 (en) 2005-02-10
DK1487972T3 (en) 2015-10-19
US20150266971A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
EP1487972B1 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
HK1226095A1 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
US20080176268A1 (en) MN Gene and Protein
US7087727B2 (en) Periostin-based diagnostic assays
WO2003100029A2 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
EP3031910B1 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
AU2008200868B2 (en) Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erb-B2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes
HK1177474B (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
US20100056611A1 (en) MN/CA9 Splice Variants

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220224